Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Neuroplast logo — First-in-kind stem cell therapy to combat neurodegenerative...

Neuroplast

First-in-kind stem cell therapy to combat neurodegenerative diseases, giving back treatment perspective to millions

Founded 2014 The Netherlands The Netherlands 8 employees Series B Total: $14.00M Health and Wellness

General Information

Company Name Neuroplast
Founded Year 2014
Location The Netherlands The Netherlands +2
Employees 8
Industries Health and Wellness
Funding Stage Series B
Social

Get notified when Neuroplast moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Neuroplast

Neuroplast B.V. creates neuro-regenerative medicine with dedicated consistent standards and protocols. The Dutch medical biotech company, established in 2014, has secured a €10.00M Series B investment from NV Industriebank LIOF, Brightlands Venture Partners, Lumana Invest as of 17th November 2021. The company has gained recognition for its excellence in clinical research and protocols, manufacturing process, and evidence-based effectiveness. Neuroplast prioritises the introduction of top-notch stem cell products for global use, bridging the gap between laboratory testing and actual treatment. With its focus on neuro-regenerative personalised medicine, which holds great promise as a treatment, Neuroplast B.V. exemplifies a commitment to dedicated standards and regulations essential for success in this industry. With its headquarters in The Netherlands, Neuroplast is positioned to make significant contributions to the field of neuro-regenerative medicine.

Taxonomy: Neuroplast B.V., neuro-regenerative medicine, standards and protocols, personalized medicine, clinical research, manufacturing process, evidence-based effectiveness, stem cell products, global use, laboratory testing, treatment, biotech company

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 3
Investor Investor Investor
17 Nov 2021
Venture Round •••••• 3
Investor Investor Investor
19 Feb 2020

Neuroplast Alternatives & Competitors

Neuroplast vs
Stem Cell Cure India
Stem Cell Cure India India

India's Leading Stem Cell Therapy Centre

3 employees

FAQ About Neuroplast

First-in-kind stem cell therapy to combat neurodegenerative diseases, giving back treatment perspective to millions
Neuroplast was founded in 2014.
Neuroplast is headquartered in The Netherlands.
Neuroplast operates in the following industries: Health and Wellness.
Neuroplast has approximately 8 employees.
Neuroplast has completed 2 funding rounds, raising a total of $14.00M. The latest funding stage is Series B.
Top alternatives and competitors to Neuroplast include Stem Cell Cure India. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Neuroplast and Stem Cell Cure India are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Neuroplast and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy